Rooting Out Recurrent Breast Cancer
In this issue of the Journal of Clinical Investigation, researchers led by Carlos Arteaga at Vanderbilt University identified a protein, TGF-β, that is highly expressed in triple negative breast cancer cells after chemotherapy.
In a mouse model of breast cancer, TGF-β both diverted cells down a path to becoming cancerous and allowed for cancer to come back after treatment. Importantly, loss of TGF-β prevented tumor recurrence in mice. These studies identify a mechanism by which cancer cells elude standard chemotherapy and provide a rationale for testing the therapeutic potential of agents that block TGF-β.
TITLE: TGFβ inhibition enhances chemotherapy action against triple negative breast cancer
View this article at: http://www.jci.org/articles/view/65416?key=201b874c7a54cc627c43